Clinical Trials

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe Hemoglobinopathies

This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).

Locations

1 United States site

Age

2 to 30 Years

Phase

Early Phase 1

LEARN MORE
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A Single Arm Open Label Trial, “BRAIN SAFE II”

Worldwide, an estimated 200,000 babies are born with Sickle Cell Anemia (SCA) annually.

Locations

1 Uganda site

Age

3 to 9 Years

Genotypes

HbSS

Phase

Phase 3

LEARN MORE
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.

Locations

10 United States sites

Age

3 to 21 Years

Phase

Phase 3

LEARN MORE
A Phase I/II Study of the Correction of a Single Nucleotide Mutation (Adenosine –> Thymine [A–>T]) in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease

This study is a first-in-human, single-arm, open-label Phase I/II study of GPH101 in approximately 15 participants, diagnosed with severe Sickle Cell Disease.

Locations

1 United States site

Age

12 to 40 Years

Phase

Phase 1/Phase 2

LEARN MORE
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD).

Locations

2 United States sites

Age

12 to 35 Years

Phase

Phase 1/Phase 2

LEARN MORE
Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room

The management of pain in the emergency department is a major issue, especially for sickle cell patients who regularly consult for vaso-occlusive seizure (VOS).

Locations

1 France site

Age

> 18 Years

Phase

N/A

LEARN MORE
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition

This study is design to assess the effects of an increase in nutritional intake on the bone mineral density of children with sickle cell disease, for 12 months.

Age

3 to 16 Years

Genotypes

SS, SC

Phase

N/A

LEARN MORE
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)

Sickle Cell Anaemia (SCA) is an inherited disease that makes the body produce red blood cells with abnormal sickle-shaped cells.

Age

6 to 15 Years

Genotypes

HbSS

Phase

Phase 2/Phase 3

LEARN MORE
Physical Rehabilitation in Adults With Sickle Cell Anemia: Effects on Muscle Function, Functional Capacity and Quality of Life

Sickle cell anemia (SCA) is one of the most neglected diseases worldwide, according to the World Health Organization.

Locations

1 Brazil site

Age

18 to 60 Years

Phase

N/A

LEARN MORE
Stroke Prevention in Young Adults With Sickle Cell Anemia

Sickle cell disease (SCD) is the most common genetic disease, affecting about 25 million people worldwide.

Locations

1 United States site

1 Nigeria site

Age

16 to 26 Years

LEARN MORE